NCT01425580View on ClinicalTrials.gov

Liraglutide and Heart Failure in Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Congestive Heart FailureType 2 Diabetes Mellitus
Interventions
DRUG

liraglutide

1.8 mg s.c. (QD)

DRUG

glimepiride

4 mg p.o. (QD)

DRUG

Metformin

500 mg p.o. (BID)

Trial Locations (2)

118 83

Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm

Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB, Stockholm

All Listed Sponsors
collaborator

Örebro University, Sweden

OTHER

lead

Thomas Nystrom

OTHER

NCT01425580 - Liraglutide and Heart Failure in Type 2 Diabetes | Biotech Hunter | Biotech Hunter